SillaJen, Inc. (215600.KQ)
- Previous Close
3,450.00 - Open
3,410.00 - Bid 3,245.00 x --
- Ask 3,250.00 x --
- Day's Range
3,225.00 - 3,435.00 - 52 Week Range
1,873.00 - 5,090.00 - Volume
1,576,916 - Avg. Volume
1,997,394 - Market Cap (intraday)
448.679B - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
www.sillajen.comRecent News: 215600.KQ
View MorePerformance Overview: 215600.KQ
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 215600.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 215600.KQ
View MoreValuation Measures
Market Cap
476.29B
Enterprise Value
365.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
105.94
Price/Book (mrq)
3.61
Enterprise Value/Revenue
93.14
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.79%
Return on Equity (ttm)
-28.05%
Revenue (ttm)
3.93B
Net Income Avi to Common (ttm)
-26.53B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
121.27B
Total Debt/Equity (mrq)
8.11%
Levered Free Cash Flow (ttm)
-21.69B